WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Patients with chronic myeloid leukaemia (CML) have been shown to have impaired innate and adaptive immunity, although most pronounced at diagnosis, leading to the decision of the Department of Health and Social Care (DHSC) to classify in the clinically extremely vulnerable groups ‘people having other targeted cancer treatments that can affect the immune system, such as protein kinase inhibitors’.